Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Gefitinib Receives European Licence For The Treatment Of Lung Cancer For Patients With EGFR Activating Mutation Positive Tumours
AstraZeneca announced that it has received a licence by the European Medicines Agency (EMEA) for its oral targeted anti-cancer drug, gefitinib, for EGFR (epidermal growth factor receptor-tyrosine kinase) activating mutation positive patients with Non Small Cell Lung Cancer (NSCLC). NSCLC is the most common type of lung cancer and accounts for 80% of all lung cancer cases. [1] The licence means that for the first time, thousands [2] of patients undergoing first line treatment of NSCLC in the UK may benefit from a more effective, [3] oral alternative to doublet chemotherapy (UK standard of care) without many of the side effects associated with chemotherapy. [3]
generic viagra online
Differences In Treatments And Outcomes Of Patients With Second Primary Lung Cancers Versus Those With One Primary Lung Identified
Patients with second primary lung cancers (SPLC), when compared to those with one primary lung cancer (OPLC), are more likely to have localized disease at the time of diagnosis and are more likely to receive surgical treatment rather than radiation treatment. However, patients with SPLC have a 12% higher lung cancer specific mortality, Fox Chase Cancer Center researchers reported at the annual meeting of the International Association for the Study of Lung Cancer. Drugshop to buy zoloft online and other pills.
News of the day
Glutaric Aciduria Type I: Therapy Should Extend Beyond Childhood
By systematically analysing MRI changes occuring in the brains of children with the metabolic disease glutaric aciduria type I researchers at Heidelberg University Hospital have succeeded for the first time in demonstrating reversible and permanent brain damage as well as elucidating its temporal evolution.
Oncology

A Closer Look At The I-Con™ - Isolation And Containment For Pandemic Control

American Innovative Research (A.I.R.) cofounders, David Palmer and Judy Piscione, explain how the impact of the avian flu pandemic originally motivated their company"s researching a home option of an isolation and containment unit. A.I.R. CEO Palmer states that he and Piscione leveraged decades of success in biomedical research and semiconductor clean-room technology to found American Innovative Research Corp. Palmer defines A.I.R. as a health and wellness technology company focused on providing advanced protection against airborne viruses. A.I.R. COO Piscione explains the I-Con™"s role in today "s H1N1 swine flu pandemic. Piscione describes the I-Con™ as a portable air purification and sterilization product for household, residential facility or institutional use. According to Piscione, their unit was specifically designed to reproduce the same airflow patterns that are used in hospitals and biological research facilities to create either isolation or containment. American Innovative Research Corp. is a Massachusetts, U.S.A. Company dedicated to the development of advanced technology for use in household and institutional airborne contamination purification and protection. American Innovative Research


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009